Updated Jul 16, 2026
Reitan Colleen F has filed 2 SEC Form 4 filings across 2 companies in the last 90 days — active on both sides. Lifetime open-market purchases: $10K. Lifetime open-market sales: $8.43M.
Colleen F. Reitan is a corporate director known for her role at Alnylam Pharmaceuticals, Inc., where she serves on the board. She has experience in the pharmaceutical and biotechnology sectors, contributing to strategic oversight and governance.
| Role | Director |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-05 | MYGN | MYRIAD GENETICS INC | A — Grant or award | 59.7K | $0.00 | |
| 2026-05-22 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | A — Grant or award | 671 | $0.00 | |
| 2025-09-09 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 25 | $480.98 | $12K |
| 2025-09-09 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 1.4K | $479.55 | $665K |
| 2025-09-09 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 1.4K | $478.67 | $694K |
| 2025-09-09 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 1.2K | $477.47 | $565K |
| 2025-09-09 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 972 | $476.31 | $463K |
| 2025-09-09 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 951 | $474.85 | $452K |
| 2025-09-09 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 838 | $474.22 | $397K |
| 2025-09-09 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 823 | $472.82 | $389K |
| 2025-09-09 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 222 | $471.25 | $105K |
| 2025-09-09 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 799 | $464.36 | $371K |
| 2025-09-09 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 1.7K | $463.00 | $765K |
| 2025-09-09 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 2.3K | $461.92 | $1.06M |
| 2025-09-09 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 473 | $460.71 | $218K |
| 2025-09-09 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 1.4K | $459.73 | $645K |
| 2025-09-09 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 1.9K | $458.86 | $866K |
| 2025-09-09 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 1.6K | $457.44 | $752K |
| 2025-09-09 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | M — Option exercise | 18.0K | $100.65 | $1.81M |
| 2024-08-29 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | A — Grant or award | 775 | $0.00 |
Colleen F. Reitan is a corporate director known for her role at Alnylam Pharmaceuticals, Inc., where she serves on the board. She has experience in the pharmaceutical and biotechnology sectors, contributing to strategic oversight and governance.…
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 2 open-market purchases ($10K) and 17 open-market sales ($8.43M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Reitan Colleen F profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.